


BMS-191095

Cat. No.:	HY-14256		
CAS No.:	166095-21-2		
Molecular Formula:	C ₂₂ H ₂₁ ClN ₄ O ₂		
Molecular Weight:	408.88		
Target:	Potassium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (244.57 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4457 mL	12.2285 mL	24.4571 mL
	5 mM	0.4891 mL	2.4457 mL	4.8914 mL
	10 mM	0.2446 mL	1.2229 mL	2.4457 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (6.11 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (6.11 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.11 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels^{[1][2][3]}.

In Vitro

BMS-191095 (50 μmol/L) induces mitochondrial depolarization of vascular smooth muscle (VSM) cells from SD rats^[1].
BMS-191095 (10-100 μmol/L) dose-dependently induces vasodilation in endothelium denuded cerebral arteries^[1].
BMS-191095 (50 μmol/L) increases the frequency of calcium sparks in VSM cells^[1].
BMS-191095 (0-1500 μM) inhibits human platelet aggregation induced by collagen and thrombin with IC₅₀ values of 63.9 and

104.8 μ M, respectively^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-191095 (2.5 or 25 μ g; intraventricular infusion, 30 min/60 min/24 hours before the induction of ischemia, once) reduces neuronal damage in rats with transient focal cerebral ischemia^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats with the induction of ischemia induced by middle cerebral artery occlusion (MCAO) ^[3]
Dosage:	2.5 or 25 μ g
Administration:	Intraventricular infusion; 30 min/60 min/24 hours before the induction of ischemia, once
Result:	Reduced total infarct volume in rats with of pretreat dose of 25 mg and 24 h before MCA. Induced a rapid mitochondrial depolarization.

CUSTOMER VALIDATION

- Pharmaceuticals. 2023, 16(2), 225.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Cho MR, et al. BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels. Arch Pharm Res. 2005 Jan;28(1):61-7.

[2]. Mayanagi K, et al. The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007 Feb;27(2):348-55.

[3]. Katakam PV, et al. Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307(4):H493-503.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA